ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 0824 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Ying Shan1, Page Moore1, Lin Guo1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: Previous data from the Corrona RA registry, conducted in a US clinical practice setting, demonstrated that patients (pts) with RA who were ACPA+ had…
  • Abstract Number: 1479 • ACR Convergence 2020

    Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry

    Jasmin Kuemmerle-Deschner1, Birgit Kortus-Goetze2, Michael Borte3, Ivan Foeldvari4, Gerd Horneff5, Ales Janda6, Tilmann Kallinich7, Prasad T. Oommen8, Catharina Schuetz9, Frank Weller-Heinemann10, Julia Weber-Arden11 and Norbert Blank12, 1University Hospital Tuebingen, Tuebingen, Germany, 2Division of Nephrology, University of Marburg, Germany, Marburg, Germany, 3ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, 4Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 5Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 6Department of Pediatrics, University Hospital Ulm, Germany, Ulm, Germany, 7Charite, Berlin, Germany, 8Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 9Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, 10Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, 11Novartis Pharma GmbH, Nuremberg, Germany, 12Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany

    Background/Purpose: In the treatment of monogenic autoinflammatory diseases (AID), a heterogeneous group of diseases with excessive interleukin (IL)-1β release and severe systemic and organ inflammation,…
  • Abstract Number: 0058 • ACR Convergence 2020

    Drug Retention and Discontinuation of Biological DMARDs and Novel Small Molecules: Data from the Singapore National Biologics Registry

    Li Wearn Koh1, Man Hua Aw2, Preeti Dhanasekaran3, Rosa Lim Mui San1, Stephanie Wong4, Xanthe Chua5, Wei Joo Choy1, Manjari Lahiri6 and Siaw Ing Yeo2, 1Tan Tock Seng Hospital, Singapore, Singapore, 2Singapore General Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Clinical Research and Innovation Office, Tan Tock Seng Hospital Singapore, Singapore, Singapore, 5Tan Tock Seng Hospital, Singapore, Singapore, Singapore, 6National University Hospital, Singapore, Singapore

    Background/Purpose: To describe drug retention rate and reasons for discontinuation of biological disease modifying anti-rheumatic drugs ( bDMARD) and novel small molecules in patients from…
  • Abstract Number: 0829 • ACR Convergence 2020

    International Comparison of Japanese and US Cross Country Utilization of RA Medications

    Hisashi Yamanaka1, Mitsumasa Kishimoto2, Kazuhisa Nakano3, Kenta Misaki4, Yuji Yamanishi5, Hiroaki Dobashi6, Masamitsu Natsumeda7, Toshiaki Miyamoto8, Koichi Amano9, Akira Sagawa10, Norihiko Koido11, Corrona Japan Consortium12, Leslie Harrold13, Tin-chi Lin13, Jeffrey Greenberg14 and Yoshiya Tanaka3, 1Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, 2Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 3The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 4Kitaharima Medical Center, Ono, Japan, 5Hiroshima Rheumatology Clinic, Hiroshima, Japan, 6Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 7Mabi Memorial Hospital, Kurashiki, Japan, 8Seirei Hamamatsu General Hospital, Hamamatsu, Japan, 9Saitama Medical Center, Kawagoe, Japan, 10Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 11Kawasaki RA & IM Clinic, Kawasaki, Japan, 12Corrona Japan Consortium, Japan, Japan, 13Corrona, LLC, Waltham, MA, 14Corrona, LLC and NYU School of Medicine, Waltham, MA

    Background/Purpose: Little is known regarding differences in DMARD utilization across countries. A better understanding is needed to contextualize findings from different countries.1 Using the same…
  • Abstract Number: 1632 • ACR Convergence 2020

    Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry

    Joerg Henes1, Norbert Blank2, Michael Borte3, Ivan Foeldvari4, Gerd Horneff5, Markus Hufnagel6, Tilmann Kallinich7, Birgit Kortus-Goetze8, Catharina Schuetz9, Frank Weller-Heinemann10, Julia Weber-Arden11 and Jasmin Kuemmerle-Deschner12, 1Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, 2Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, 3ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, 4Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 5Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 6Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, 7Charite, Berlin, Germany, 8Division of Nephrology, University of Marburg, Germany, Marburg, Germany, 9Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, 10Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, 11Novartis Pharma GmbH, Nuremberg, Germany, 12University Hospital Tuebingen, Tuebingen, Germany

    Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully  treated with the anti-IL-1ß inhibitor canakinumab.…
  • Abstract Number: 0178 • ACR Convergence 2020

    Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Bryant England1, Huifeng Yun2, Lang Chen3, Kaleb Michaud1, Ted Mikuls1 and Jeffrey R Curtis2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Although a treat-to-target strategy is endorsed in rheumatoid arthritis (RA) treatment guidelines, its routine implementation in real-world settings, particularly in the context of multimorbidity,…
  • Abstract Number: 0834 • ACR Convergence 2020

    Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry

    Stefano Fiore1, Lang Chen2, Cassie Clinton2, Huifeng Yun2, Amy Praestgaard3, Kerri Ford3 and Jeffrey R Curtis2, 1Sanofi, Bridgewater, NJ, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Sanofi, Cambridge, MA

    Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…
  • Abstract Number: 1665 • ACR Convergence 2020

    Sociodemographic and Clinical Predictors of Childhood-Onset SLE Disease Activity in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Emily Smitherman1, Rouba Chahine1, Timothy Beukelman1, Andrea Knight2, AKM Rahman1, Mary Beth Son3, Jeffrey R Curtis4 and Aimee Hersh5, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3Boston Children's Hospital, Boston, MA, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5University of Utah and Primary Children's Hospital, Salt Lake City

    Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for early morbidity and mortality, but predictors of moderate/high cSLE disease activity have…
  • Abstract Number: 047 • 2020 Pediatric Rheumatology Symposium

    Patients with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics and Inception Cohorts

    Yongdong Zhao1, Timothy Beukelman 2, Yukiko Kimura 3, Mara Becker 4, Sarah Ringold 5, Anne Dennos 6 and Laura Schanberg 7 for the CARRA investigators, 1University of Washington, Seattle, 2University of Alabama at Birmingham, Birmingham, 3Hackensack Meridian School of Medicine, Hackensack, 4Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, 5Seattle Children's, Seattle, 6Duke University, Durham, 7Duke University Hospital, DURHAM

    Background/Purpose: In July 2015, the CARRA Registry was re-established as a multi-center observational study that collects essential data from patients with childhood-onset rheumatic diseases. The…
  • Abstract Number: 074 • 2020 Pediatric Rheumatology Symposium

    Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)

    Ming Min 1, Catherine Gibson 2, Mark Friswell3, Tania Crotti 4 and Christina Boros 5, 1Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, North Adelaide, South Australia, Australia, 2Women's and Children's Health Network, North Adelaide, South Australia, Australia, 3Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, South Australia, Australia, 4Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia, 5Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, Australia

    Background/Purpose: Patient outcomes and experiences are key components in the measurement of overall health outcomes in JIA and can be measured by validated PROMs and…
  • Abstract Number: 087 • 2020 Pediatric Rheumatology Symposium

    Standardizing Care and Fostering Systemic Autoinflammatory Disease (SAID) Research Through the CARRA Autoinflammatory Disease Network

    Grant Schulert1, Julie Cherian 2, Theresa Wampler Muskardin 3, Marinka Twilt 4, Shoghik Akoghlanian 5, Gil Amarilyo 6, Dilan Dissanayake 7, Karen Durrant 8, Polly Ferguson 9, Maria Gutierrez 10, Liora Harel 11, Jonathan Hausmann 12, Merav Heshin Bekenstein 13, Ronald Laxer 7, Aleksander Lenert 9, Suzanne Li 14, Greg Licameli 15, Geraldina Lionetti 16, Ian Michelow 17, Lakshmi Moorthy 18, Evan Propst 19, Vivian Saper 20, Hemalatha Srinivasalu 21, Yuriy Stepanovskiy 22, Akaluck Thatayatikom 23, Lori Tucker 24, Peter Wright 25, Cagri Yildirim-Toruner 5, Fatma Dedeoglu 15 and Sivia Lapidus 26 for the CARRA investigators, 1Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, 2Stony Brook Children's Hospital, Stony Brook, 3Colton Center for Autoimmunity, NYU School of Medicine, New York, 4Alberta Children's Hospital, Calgary, Canada, 5Nationwide Children's Hospital, Columbus, 6Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, 7The Hospital for Sick Children and University of Toronto, Toronto, Canada, 8Kaiser Permanente San Francisco Medical Center and Autoinflammatory Alliance, San Francisco, 9University of Iowa Carver College of Medicine, Iowa City, 10Johns Hopkins University School of Medicine, Baltimore, 11Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, 12Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 13Dana Children’s Hospital of Tel Aviv Medical Center, Binyamina, Israel, 14Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 15Boston Children's Hospital, Boston, 16UCSF Benioff Children’s Hospital, Oakland, 17Alpert Medical School, Brown University, Providence, 18Rutgers Robert Wood Johnson Medical School, Metuchen, 19The Hospital for Sick Children, University of Toronto, Toronto, Canada, 20Stanford University, Los Altos, 21Children's National Medical Center, Washington, 22Shupyk National Medical Academy of Postgraduate Education, Kiev, 23University of Florida, Gainesville, 24BC Children's Hospital, Vancouver, British Columbia, Canada, 25Dartmouth-Hitchcock Medical Center, Lebanon, 26The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood

    Background/Purpose: International registries have significantly enhanced the understanding of the genetics, phenotype, prognosis, and treatment of Systemic Autoinflammatory Diseases (SAIDs) that could be further augmented…
  • Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium

    Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry

    Natalie Shiff1, Aimee Lougee 2, Roland Matsouaka 2, David Collier 3, Yukiko Kimura 4, Dax Rumsey 5, Jennifer Schenfeld 6, Scott Stryker 7, Marinka Twilt 8 and Timothy Beukelman 9, 1Florida, Gainesville, 2Duke University, Durham, 3Amgen, Thousand Oaks, 4Hackensack Meridian School of Medicine, Hackensack, 5University of Alberta, Edmonton, Canada, 6Amgen, Long Beach, 7Amgen, Inc, San Francisco, 8Alberta Children's Hospital, Calgary, Canada, 9University of Alabama at Birmingham, Birmingham

    Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
  • Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium

    Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration

    Erin Balay1, Jennifer Weiss 2, Y. Ingrid Goh 3, Nathan Rubin 4 and Danielle Bullock 4, 1University of Minnesota, saint paul, 2Hackensack University Medical Center, Hackensack, 3The Hospital for Sick Children, Toronto, Canada, 4University of Minnesota, Minneapolis

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
  • Abstract Number: 1543 • 2019 ACR/ARP Annual Meeting

    Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry

    Proton Rahman 1, Regan Arendse 2, Isabelle Fortin 3, Andrew Chow 4, Majed Khraishi 5, Suneil Kapur 6, Michel Zummer 7, Raheem Kherani 8, Jonathan Chan 9, Emmanouil Rampakakis 10, Meagan Rachich 11, Odalis Asin-Milan 11, Allen Lehman 11 and Francois Nantel11, 1Memorial University, Newfoundland, NL, Canada, 2University of Saskatchewan, Saskatoon, SK, Canada, 3Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, 4Credit Valley Rheumatology, Mississauga, ON, Canada, 5Nexus Clinical Research, Memorial University of Newfoundland, St. Johns, NL, Canada, 6University of Ottawa, Ottawa, ON, Canada, 7Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 8University of British Columbia, Richmond, BC, Canada, 9Artus Health Clinic, Vancouver, BC, Canada, 10JSS Medical Research, Montreal, Canada, 11Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose of…
  • Abstract Number: 1544 • 2019 ACR/ARP Annual Meeting

    Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry

    Proton Rahman 1, Ariel Masetto 2, Michelle Teo 3, Pauline Boulos 4, Dalton Sholter 5, Suneil Kapur 6, Emmanouil Rampakakis 7, Meagan Rachich 8, Odalis Asin-Milan 8, Allen Lehman 8 and Francois Nantel8, 1Memorial University, Newfoundland, NL, Canada, 2Université de Sherbrooke, Sherbrooke, QC, Canada, 3Balfour Medical Clinic, Penticton, BC, Canada, 4McMaster University, Hamilton, ON, Canada, 5Rheumatology Associates, Edmonton, AB, Canada, 6University of Ottawa, Ottawa, ON, Canada, 7JSS Medical Research, Montreal, Canada, 8Janssen Inc., Toronto, ON, Canada

    Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled ankylosing spondylitis (AS) (radiographic axial SpA) patients treated with subcutaneous…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology